Literature DB >> 20613638

HIV-1 gp120-induced injury to the blood-brain barrier: role of metalloproteinases 2 and 9 and relationship to oxidative stress.

Jean-Pierre Louboutin1, Lokesh Agrawal, Beverly A S Reyes, Elisabeth J Van Bockstaele, David S Strayer.   

Abstract

Blood-brain barrier (BBB) disruption occurs during human immunodeficiency virus encephalopathy, but the mechanisms involved are not understood. We studied how acute and ongoing exposure to human immunodeficiency virus 1 envelope gp120 alters BBB structure and permeability. Intravenous Evans blue, given before stereotaxic gp120 injection into the caudate putamen of rats, was rapidly extravasated. Gelatinolytic activity, studied by in situ zymography, was increased after gp120 administration and was localized within cerebral vessel walls. The gp120 increased the expression of matrix metalloproteinases (MMPs) 2 and 9. Laminin and claudin-5, key BBB components and targets of both MMPs, were greatly reduced upon gp120 administration. The gp120 increased lipid peroxidation in the vascular endothelium and in neurons. Prior administration of rSV40 vectors carrying the antioxidant enzymes Cu/Zn superoxide dismutase or glutathione peroxidase protected from gp120-induced BBB damage. N-methyl-D-aspartate receptor activation upregulated pro-MMP-9 and increased MMP-9 gelatinase activity, and memantine, an N-methyl-D-aspartate receptor blocker, mitigated gp120-induced BBB abnormalities. Using intra-caudate putamen SV(gp120) to test the effects of chronic exposure to expressed gp120, we determined that oxidant stress and increased BBB permeability occurred as in acute exposure. These data indicate that both direct administration and cellular expression of gp120 lead to disruption of the BBB by increasing MMPs and reducing vascular tight junction proteins via mechanisms involving reactive oxygen species generation and oxidant injury.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20613638      PMCID: PMC4707960          DOI: 10.1097/NEN.0b013e3181e8c96f

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  72 in total

1.  Dendritic cell transmigration through brain microvessel endothelium is regulated by MIP-1alpha chemokine and matrix metalloproteinases.

Authors:  Alla L Zozulya; Emily Reinke; Dana C Baiu; Jozsef Karman; Matyas Sandor; Zsuzsanna Fabry
Journal:  J Immunol       Date:  2007-01-01       Impact factor: 5.422

2.  CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV)-infected leukocytes across the blood-brain barrier: a potential mechanism of HIV-CNS invasion and NeuroAIDS.

Authors:  Eliseo A Eugenin; Kristin Osiecki; Lillie Lopez; Harris Goldstein; Tina M Calderon; Joan W Berman
Journal:  J Neurosci       Date:  2006-01-25       Impact factor: 6.167

3.  Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats.

Authors:  Toshiaki Aoki; Toshihisa Sumii; Tatsuro Mori; Xiaoying Wang; Eng H Lo
Journal:  Stroke       Date:  2002-11       Impact factor: 7.914

4.  Matrix metalloproteinase-9 undergoes expression and activation during dendritic remodeling in adult hippocampus.

Authors:  Arek Szklarczyk; Joanna Lapinska; Marcin Rylski; Ronald D G McKay; Leszek Kaczmarek
Journal:  J Neurosci       Date:  2002-02-01       Impact factor: 6.167

5.  HIV-1 gp120 proteins alter tight junction protein expression and brain endothelial cell permeability: implications for the pathogenesis of HIV-associated dementia.

Authors:  Georgette D Kanmogne; Charles Primeaux; Paula Grammas
Journal:  J Neuropathol Exp Neurol       Date:  2005-06       Impact factor: 3.685

6.  Gelatinase B and TIMP-1 are regulated in a cell- and time-dependent manner in association with neuronal death and glial reactivity after global forebrain ischemia.

Authors:  Santiago Rivera; Crystel Ogier; Jérôme Jourquin; Serge Timsit; Arkadius W Szklarczyk; Karen Miller; Andrew J H Gearing; Leszek Kaczmarek; Michel Khrestchatisky
Journal:  Eur J Neurosci       Date:  2002-01       Impact factor: 3.386

7.  Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: a possible role in blood-brain barrier dysfunction.

Authors:  Y Gasche; M Fujimura; Y Morita-Fujimura; J C Copin; M Kawase; J Massengale; P H Chan
Journal:  J Cereb Blood Flow Metab       Date:  1999-09       Impact factor: 6.200

8.  HIV-1 viral proteins gp120 and Tat induce oxidative stress in brain endothelial cells.

Authors:  Tulin Otamis Price; Nuran Ercal; Ryota Nakaoke; William A Banks
Journal:  Brain Res       Date:  2005-04-19       Impact factor: 3.252

9.  HIV-1 gp120 neurotoxicity proximally and at a distance from the point of exposure: protection by rSV40 delivery of antioxidant enzymes.

Authors:  Jean-Pierre Louboutin; Lokesh Agrawal; Beverly A S Reyes; Elisabeth J Van Bockstaele; David S Strayer
Journal:  Neurobiol Dis       Date:  2009-03-25       Impact factor: 5.996

10.  Blood-brain barrier abnormalities in the acquired immunodeficiency syndrome: immunohistochemical localization of serum proteins in postmortem brain.

Authors:  C K Petito; K S Cash
Journal:  Ann Neurol       Date:  1992-11       Impact factor: 10.422

View more
  50 in total

1.  HIV-1 envelope protein gp120 up regulates CCL5 production in astrocytes which can be circumvented by inhibitors of NF-κB pathway.

Authors:  Ankit Shah; Dhirendra P Singh; Shilpa Buch; Anil Kumar
Journal:  Biochem Biophys Res Commun       Date:  2011-09-14       Impact factor: 3.575

Review 2.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

3.  Methamphetamine and HIV-1 gp120 effects on lipopolysaccharide stimulated matrix metalloproteinase-9 production by human monocyte-derived macrophages.

Authors:  Jessica L Reynolds; Supriya D Mahajan; Ravikumar Aalinkeel; Bindukumar Nair; Donald E Sykes; Stanley A Schwartz
Journal:  Immunol Invest       Date:  2011-03-22       Impact factor: 3.657

Review 4.  HIV-1 gp120 and drugs of abuse: interactions in the central nervous system.

Authors:  Peter S Silverstein; Ankit Shah; James Weemhoff; Santosh Kumar; D P Singh; Anil Kumar
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

5.  Nitrosative Stress Is Associated with Dopaminergic Dysfunction in the HIV-1 Transgenic Rat.

Authors:  Swati Shah; Dragan Maric; Frank Denaro; Wael Ibrahim; Ronald Mason; Ashutosh Kumar; Dima A Hammoud; William Reid
Journal:  Am J Pathol       Date:  2019-07       Impact factor: 4.307

6.  Gene delivery of antioxidant enzymes inhibits human immunodeficiency virus type 1 gp120-induced expression of caspases.

Authors:  J-P Louboutin; L Agrawal; B A S Reyes; E J van Bockstaele; D S Strayer
Journal:  Neuroscience       Date:  2012-04-21       Impact factor: 3.590

7.  HIV-1 Tat and opioids act independently to limit antiretroviral brain concentrations and reduce blood-brain barrier integrity.

Authors:  Crystal R Leibrand; Jason J Paris; Austin M Jones; Quamrun N Masuda; Matthew S Halquist; Woong-Ki Kim; Pamela E Knapp; Angela D M Kashuba; Kurt F Hauser; MaryPeace McRae
Journal:  J Neurovirol       Date:  2019-05-17       Impact factor: 2.643

Review 8.  Claudins: control of barrier function and regulation in response to oxidant stress.

Authors:  Christian E Overgaard; Brandy L Daugherty; Leslie A Mitchell; Michael Koval
Journal:  Antioxid Redox Signal       Date:  2011-05-09       Impact factor: 8.401

9.  PPARα and PPARγ protect against HIV-1-induced MMP-9 overexpression via caveolae-associated ERK and Akt signaling.

Authors:  Wen Huang; Ibolya E András; Geun Bae Rha; Bernhard Hennig; Michal Toborek
Journal:  FASEB J       Date:  2011-08-12       Impact factor: 5.191

10.  Dysregulation of Alveolar Macrophage PPARγ, NADPH Oxidases, and TGFβ1 in Otherwise Healthy HIV-Infected Individuals.

Authors:  Samantha M Yeligar; Janine M Ward; Frank L Harris; Lou Ann S Brown; David M Guidot; Sushma K Cribbs
Journal:  AIDS Res Hum Retroviruses       Date:  2017-04-24       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.